Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
89bio’s home run fails to excite
The group gets a win in severe hypertriglyceridaemia, but a bigger readout in Nash awaits.
Asco 2022 – Merck’s follow-on immuno-oncology plan hits a myositis problem
ILT3 blockade shows no monotherapy activity while a combo runs into toxicity issues, but Merck presses on.
No land grab for Gemini in geographic atrophy
Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.
Biotech’s important clinical data readouts
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Novo’s Nash play takes shape
As semaglutide looks set to move into pivotal trials in Nash, Novo Nordisk lays out hopes for longer-term benefits.
Akero’s success gives a new Nash mechanism hope
Before Covid-19 came along investors were looking to several Nash catalysts in 2020, and yesterday Akero delivered on one of these.
